1-(4,5-二甲基-噻唑-2-基)-乙醇 | 7531-72-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4,5-二甲基-噻唑-2-基)-乙醇
• 英文名称: (rac)-1-(4,5-dimethyl-1,3-thiazol-2-yl)ethan-1-ol
• 英文别名: 1-(4,5-dimethyl-2-thiazolyl)ethanol；4,5-Dimethyl-2-(1-hydroxy)ethylthiazol；2-(α-Hydroxyethyl)-4,5-dimethyl-thiazol；1-(4,5-dimethyl-thiazol-2-yl)-ethanol；1-(4,5-dimethyl-1,3-thiazol-2-yl)ethanol
• CAS: 7531-72-8
• 化学式: C₇H₁₁NOS
• 分子量: 157.236
• InChiKey: GEEFPWNWTUMMKP-UHFFFAOYSA-N

物化性质

• 沸点：
  120-123 °C(Press: 10 Torr)
• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4,5-二甲基-噻唑-2-基)-乙醇 在 五氯化磷 作用下， 生成 1-(4,5-Dimethyl-2-thiazolyl)aethylchlorid
  参考文献：
  名称：

  Transmission of substituent effects in heterocyclic systems. Rates of solvolysis of substituted 1-(4-thiazolyl)ethyl chlorides

  摘要：

  DOI：

  10.1021/jo00959a017
• 作为产物：
  描述：

  4,5-二甲基噻唑 、 乙醛 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 生成 1-(4,5-二甲基-噻唑-2-基)-乙醇
  参考文献：
  名称：

  Thieme Chemistry Journal Awardees- Where are They Now? Intermolecular Cross-Acyloin Reactions by Fluoride-Promoted Additions of O-Silyl Thiazolium Carbinols

  摘要：

  已开发出将酰基阴离子等价物与脂肪醛进行加成的反应（交叉酸醇反应）。氟化铯与异丙醇作为溶剂促进了O-硅基噻唑鎓醇与多种脂肪醛的加成反应，产率为中等到良好。这些反应代表了一种通过酰基阴离子反应选择性耦合脂肪醛的通用程序，而这一过程直到现在仍然存在问题。

  DOI：

  10.1055/s-0028-1087555

文献信息

• Method and composition for rejuvinating cells, tissues organs, hair and nails
  申请人：——

  公开号：US20020188015A1

  公开（公告）日：2002-12-12

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一个实施例中，本发明涉及包含药物组合物的化合物和组合物，其中药物组合物包含这些化合物，并且相关方法解耦蛋白质、脂质、核酸和其他生物材料以及它们的任意组合的糖介导偶联。在另一个实施例中，这些组合物和相关方法在体内具有实用性，用于减少生物体暴露于内部摄入、经皮应用或其他方式的化合物或组合物时，糖介导偶联过程的有害影响。在另一个实施例中，这些组合物和相关方法对器官、细胞和组织的离体处理以及头发、指甲和皮肤的外部处理具有用处，通过改变可变性和增加组织扩散系数来使它们恢复活力。在另一个实施例中，本发明涉及新颖的化合物和药物组合物。
• Method and composition for rejuvenating cells, tissues organs, hair and nails
  申请人：——

  公开号：US06777557B2

  公开（公告）日：2004-08-17

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一种实施方式中，本发明涉及化合物和组合物，包括含有该化合物的药物组合物及相关方法，解除糖介导的蛋白质、脂质、核酸和其他生物材料及其任何组合的耦合。在另一种实施方式中，该组合物和相关方法在体内具有实用性，用于减少生物体暴露于该化合物或组合物内部时，糖介导的耦合过程的有害影响。该化合物或组合物可以通过口服、经皮应用或其他方式进行摄入。在另一种实施方式中，该组合物和相关方法适用于外体器官、细胞和组织的外体治疗，以及用于改变其可变形性和增加组织扩散系数的头发、指甲和皮肤的再生。在进一步的实施方式中，本发明涉及新型化合物和药物组合物。
• Method and composition for rejuvenating cells, tissues, organs, hair and nails
  申请人：——

  公开号：US07022721B1

  公开（公告）日：2006-04-04

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一种实施例中，本发明涉及化合物和组合物，包括含有该化合物的制药组合物以及相关方法，该方法解除糖介导的蛋白质、脂质、核酸和其他生物材料的耦合，以及任何组合。在另一种实施例中，该组合物和相关方法在体内具有实用性，用于减少有机体暴露于该化合物或组合物内部时，糖介导的耦合过程的有害影响，通过摄入、经皮应用或其他方式。在另一种实施例中，该组合物和相关方法对于外部处理头发、指甲和皮肤，以改变可变性和增加组织扩散系数，使它们恢复活力，具有外体处理器官、细胞和组织的作用。在另一种实施例中，本发明涉及新型化合物和制药组合物。
• [EN] MAP4K1 INHIBITORS<br/>[FR] INHIBITEURS DE MAP4K1
  申请人：BAYER AG

  公开号：WO2022167627A1

  公开（公告）日：2022-08-11

  The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2and R4have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及公式（I）（I）的Map4K1抑制剂，其中A，E，G，Q，R1，R2和R4的含义与说明中定义的相同，涉及包含根据本发明的化合物的制药组合物和组合物，以及创新化合物的预防和治疗用途，分别用于制造用于治疗或预防疾病的制药组合物，特别是用于肿瘤性疾病，或与异常MAP4K1信号相关的其他紊乱免疫反应或其他疾病，作为唯一药物或与其他活性成分联合使用。本发明还涉及用于制造用于治疗或预防良性增生，动脉粥样硬化疾病，败血症，自身免疫性疾病，血管疾病，病毒感染，神经退行性疾病，炎症性疾病，动脉粥样硬化疾病和男性生育控制的制药组合物的使用，分别使用上述化合物制造制药组合物。
• NOVEL 1,1-BIS(HETEROAZOLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS
  申请人：Astra Aktiebolag

  公开号：EP0765325A1

  公开（公告）日：1997-04-02